205 related articles for article (PubMed ID: 18334761)
1. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
Bakchine S; Loft H
J Alzheimers Dis; 2008 Feb; 13(1):97-107. PubMed ID: 18334761
[TBL] [Abstract][Full Text] [Related]
2. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
Bakchine S; Loft H
J Alzheimers Dis; 2007 Jul; 11(4):471-9. PubMed ID: 17656827
[TBL] [Abstract][Full Text] [Related]
3. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
4. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
[TBL] [Abstract][Full Text] [Related]
5. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S
Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Orgogozo JM; Rigaud AS; Stöffler A; Möbius HJ; Forette F
Stroke; 2002 Jul; 33(7):1834-9. PubMed ID: 12105362
[TBL] [Abstract][Full Text] [Related]
7. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
8. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials.
Farlow MR; Graham SM; Alva G
Drug Saf; 2008; 31(7):577-85. PubMed ID: 18558791
[TBL] [Abstract][Full Text] [Related]
9. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease.
Ott BR; Blake LM; Kagan E; Resnick M;
J Neurol; 2007 Mar; 254(3):351-8. PubMed ID: 17345042
[TBL] [Abstract][Full Text] [Related]
10. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
11. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
Dysken MW; Sano M; Asthana S; Vertrees JE; Pallaki M; Llorente M; Love S; Schellenberg GD; McCarten JR; Malphurs J; Prieto S; Chen P; Loreck DJ; Trapp G; Bakshi RS; Mintzer JE; Heidebrink JL; Vidal-Cardona A; Arroyo LM; Cruz AR; Zachariah S; Kowall NW; Chopra MP; Craft S; Thielke S; Turvey CL; Woodman C; Monnell KA; Gordon K; Tomaska J; Segal Y; Peduzzi PN; Guarino PD
JAMA; 2014 Jan; 311(1):33-44. PubMed ID: 24381967
[TBL] [Abstract][Full Text] [Related]
12. [Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease].
Gallarda T; Lôo H
Encephale; 2004; 30(1):69-79. PubMed ID: 15029079
[TBL] [Abstract][Full Text] [Related]
13. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.
van Dyck CH; Tariot PN; Meyers B; Malca Resnick E;
Alzheimer Dis Assoc Disord; 2007; 21(2):136-43. PubMed ID: 17545739
[TBL] [Abstract][Full Text] [Related]
14. Memantine.
Jarvis B; Figgitt DP
Drugs Aging; 2003; 20(6):465-76; discussion 477-8. PubMed ID: 12710865
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan.
Nakamura Y; Kitamura S; Homma A; Shiosakai K; Matsui D
Expert Opin Pharmacother; 2014 May; 15(7):913-25. PubMed ID: 24673497
[TBL] [Abstract][Full Text] [Related]
16. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of memantine in the treatment of dementia.
Rossom R; Adityanjee ; Dysken M
Am J Geriatr Pharmacother; 2004 Dec; 2(4):303-12. PubMed ID: 15903287
[TBL] [Abstract][Full Text] [Related]
18. Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.
Grossberg GT; Alva G; Hendrix S; Ellison N; Kane MC; Edwards J
Alzheimer Dis Assoc Disord; 2018; 32(3):173-178. PubMed ID: 29771687
[TBL] [Abstract][Full Text] [Related]
19. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
20. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease.
Emre M; Mecocci P; Stender K
J Alzheimers Dis; 2008 Jun; 14(2):193-9. PubMed ID: 18560130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
